Imprimis Pharmaceuticals Inc. and SightLife Surgical have signed an agreement in which SightLife will be offering Imprimis' autologous eye drops, Serum Tears, which have been specially formulated for patients suffering from chronic dry eye who require more than traditional treatment.
Under the new agreement, SightLife's sales team will be presenting Imprimis' eye drops to physicians and surgery centers to hospitals and other large organizations across the U.S.
"We are pleased to have accelerated the first phase of the launch of our dry eye program by partnering with the largest and most prestigious eye bank in the world," Imprimis CEO Mark Baum said, noting the relationship with would help place the company's eye drops within reach of corneal surgeons, whose patients may require unconventional treatment.
Imprimis' Serum Tears are unique in their ability to work as therapy, thanks to their chemical makeup, and treatment for surgeons to use on their patients.
"This partnership with Imprimis uniquely positions us to help the thousands of domestic physicians treating dry eye and makes this important products widely available to patients in need of these drips around the country," SightLife Surgical President and CEO Monty Montoya said.
It is estimated that 12 million individuals suffer from moderate to severe dry eye in the U.S.
Alerts Sign-up